In this week's video, Dr. Brian Durie discusses selinexor, a novel, orally administered drug that is currently ongoing clinical trials.

Bottom Line:

Selinexor is a promising new type of drug that can make a difference for myeloma patients.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Can the ASCO “Value Framework” work for myeloma patients?
Next Post
Precision Medicine: Is It a Must, a Bust—or Something in Between?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.